Skip to main content
. 2023 Jun 15;24(12):10164. doi: 10.3390/ijms241210164

Table 1.

Main results of studies investigating the effects of SGLT2i on lipid profile.

Type of Study Molecule N° of Patients Time of Follow-Up Main Results
Calapkulu et al., 2019 [54] Retrospective study Dapaglifozin 10 mg 31 patients 3 and 6 months At three months:
  • -

    non-significant changes

At six months:
  • -

    ↓ LDL

  • -

    (13.4 mg/dL)

  • -

    ↓ total cholesterol (17.6 mg/dL)

  • -

    ↓ triglyceride

  • -

    (25.9 mg/dL)
Bays et al., 2017 [55] Post-hoc analysis Dapaglifozin 10 mg 4401 patients 6 months ↑ LDL
↑ HDL
↑ total cholesterol
↓ triglycerides
Matthaei et al., 2015 [56] Phase 3b study Dapaglifozin 10 mg 219 patients 6 months ↑ LDL
↑ HDL
↑ total cholesterol
Hayashi et al., 2017 [57] Prospective study Dapaglifozin 10 mg 80 patients 3 months ↑ LDL (0.5%)
↑ HDL (10.5%)
↑ total cholesterol (2.5%)
↓ triglycerides (12.4%)
Yanai et al., 2017 [58] Retrospective study Dapaglifozin 10 mg 249 patients
(69 treated with dapaglifozin)		 3 and 6 months At three months:
non-significant changes
At six months:
  • -

    non-significant changes in LDL, total cholesterol, and triglycerides

  • -

    ↑ HDL
Zinman et al., 2015 [59] Randomized controlled trial Empaglifozin 10 or 25 mg 7028 patients 3 years ↑ LDL
↓ HDL
Tikkanen et al., 2015 [60] Phase 3 study Empaglifozin 10 or 25 mg 825 patients 14 weeks With 10 mg:
  • -

    non-significant changes

With 25 mg:
  • -

    ↑ LDL

  • -

    ↓ total cholesterol

  • -

    non-significant changes in HDL and triglycerides
Sánchez-García et al., 2020 [45] Meta-analysis of 48 randomized controlled trials Empaglifozin 10 or 25 mg
AND
Canagliflozin 100 or 300 mg		 24,782 patients Variable ↑ LDL
↑ HDL
↑ total cholesterol
↓ triglycerides
Liakos et al., 2014 [61] Meta-analysis of 10 randomized controlled trials Empaglifozin 10 or 25 mg 6203 patients Variable ↑ LDL (4.5–6.5%)
Neal et al., 2014 [62] Randomized controlled trial Canaglifozin 100 or 300 mg 10,142 patients Up to 78 weeks ↑ LDL
↑ HDL
Bode et al., 2015 [63] Phase 3 study Canaglifozin 100 or 300 mg 714 patients 104 weeks ↑ LDL
↑ HDL
↓ triglycerides

Abbreviations: HDL = high-density lipoprotein; LDL = low-density lipoprotein. ↑ = raised. ↓ = reduced.